Sensei Biotherapeutics, Inc.
NASDAQ:SNSE
0.5004 (USD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 2.846 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0.135 | 0.137 | 0.135 | 0.455 | 0.491 | 0.477 | 0.469 | 0.451 | 0.44 | 0.448 | 0.329 | 0.136 | 0.122 | 0.098 | 0 | 0 | 0 | 0 | 0 |
Gross Profit
| -0.135 | -0.137 | 2.711 | -0.455 | -0.491 | -0.477 | -0.469 | -0.451 | -0.44 | -0.448 | -0.329 | -0.136 | -0.122 | -0.098 | 0 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0 | 0 | 0.953 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 4.584 | 4.917 | 4.493 | 3.818 | 4.784 | 5.204 | 7.345 | 9.19 | 6.393 | 7.455 | 5.956 | 6.443 | 5.898 | 3.365 | 2.556 | 3.576 | 2.858 | 2.195 | 2.425 |
General & Administrative Expenses
| 3.203 | 3.813 | 3.649 | 3.919 | 5.393 | 5.804 | 5.703 | 4.751 | 4.319 | 5.032 | 3.457 | 3.873 | 3.886 | 4.604 | 2.521 | 1.788 | 1.311 | 1.908 | 0.982 |
Selling & Marketing Expenses
| -0.135 | -0.137 | -0.135 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 3.068 | 3.676 | 3.514 | 3.919 | 5.393 | 5.804 | 5.703 | 4.751 | 4.319 | 5.032 | 3.457 | 3.873 | 3.886 | 4.604 | 2.521 | 1.788 | 1.311 | 1.908 | 0.982 |
Other Expenses
| 0 | -0.002 | -0.067 | 0.613 | 0.068 | 0.831 | 1.565 | 0.02 | 0 | 0 | 0 | 0.631 | -0.028 | -0.003 | 0.738 | 0 | 0 | 0 | 0 |
Operating Expenses
| 7.652 | 8.593 | 8.007 | 7.737 | 10.177 | 11.008 | 13.048 | 13.941 | 10.712 | 12.487 | 9.413 | 10.316 | 9.784 | 7.969 | 5.077 | 5.364 | 4.169 | 4.103 | 3.407 |
Operating Income
| -7.787 | -8.73 | -8.142 | -7.737 | -10.177 | -11.008 | -13.048 | -13.941 | -10.712 | -12.487 | -9.413 | -10.316 | -9.784 | -7.969 | -5.077 | -5.364 | -4.907 | -4.103 | -3.407 |
Operating Income Ratio
| 0 | 0 | -2.861 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 0.645 | 0.738 | 0.728 | 0.613 | -0.123 | 0.831 | 0.816 | 0.525 | 0.177 | 0.082 | 0.019 | 0.631 | -0.028 | -0.003 | -1.689 | -0.003 | -0.738 | 1.04 | -1.902 |
Income Before Tax
| -7.142 | -7.992 | -7.414 | -7.124 | -9.386 | -10.177 | -12.232 | -13.416 | -10.535 | -12.405 | -9.366 | -9.685 | -9.771 | -7.972 | -5.131 | -5.367 | -4.91 | -4.692 | -6.705 |
Income Before Tax Ratio
| 0 | 0 | -2.605 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| 0 | 0.094 | 1.457 | -0.332 | 0.106 | -1.231 | 0.209 | -0.525 | -0.177 | -0.082 | -0.047 | -0.631 | -0.013 | 0.003 | 0.054 | 0.003 | 0.003 | 0.589 | 3.298 |
Net Income
| -7.142 | -7.992 | -7.414 | -7.124 | -9.386 | -8.946 | -12.441 | -12.891 | -10.358 | -12.323 | -9.366 | -9.685 | -9.771 | -7.972 | -5.131 | -5.367 | -4.91 | -4.692 | -6.705 |
Net Income Ratio
| 0 | 0 | -2.605 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| -0.28 | -0.32 | -0.3 | -0.28 | -0.31 | -0.29 | -0.4 | -0.42 | -0.34 | -0.4 | -0.31 | -0.32 | -0.32 | -0.42 | -0.27 | -0.44 | -0.4 | -0.38 | -0.54 |
EPS Diluted
| -0.28 | -0.32 | -0.3 | -0.28 | -0.31 | -0.29 | -0.4 | -0.42 | -0.34 | -0.4 | -0.31 | -0.32 | -0.32 | -0.42 | -0.27 | -0.44 | -0.4 | -0.38 | -0.54 |
EBITDA
| -7.652 | -8.593 | -8.007 | -7.737 | -8.825 | -11.008 | -14.257 | -13.064 | -10.043 | -11.843 | -8.75 | -10.316 | -9.624 | -7.969 | -5.334 | -5.3 | -4.117 | -4.08 | -3.384 |
EBITDA Ratio
| 0 | 0 | -2.813 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |